Rhythm Pharmaceuticals (RYTM)
89.34
-1.56 (1.72%)
Upcoming Events
Latest Headlines
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
October 21, 2026 8:00 AM - StreetInsider
William Blair Starts Rhythm Pharmaceuticals (RYTM) at Outperform
October 16, 2026 3:11 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Lowered to $145 at JPMorgan
October 15, 2026 9:10 AM - StreetInsider
Rhythm Pharmaceuticals launches IMCIVREE in Japan for hypothalamic obesity
October 13, 2026 7:30 PM - StreetInsider
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
October 13, 2026 7:30 PM - StreetInsider
Form SCHEDULE 13G RHYTHM PHARMACEUTICALS, Filed by: JPMORGAN CHASE & CO
October 13, 2026 1:38 PM - SEC Filing
Rhythm Pharmaceuticals (RYTM) PT Raised to $130 at H.C. Wainwright
October 12, 2026 6:50 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Raised to $159 at RBC Capital
October 8, 2026 8:27 AM - StreetInsider
Health Canada approves Rhythm's Imcivree for hypothalamic obesity
September 22, 2026 8:02 AM - StreetInsider
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
September 22, 2026 8:00 AM - StreetInsider
Form 4 RHYTHM PHARMACEUTICALS, For: Sep 14 Filed by: Meeker David P
September 14, 2026 7:37 PM - SEC Filing
Form 144 RHYTHM PHARMACEUTICALS, Filed by: Meeker David P
September 14, 2026 4:50 PM - SEC Filing
Leerink Assumes Rhythm Pharmaceuticals (RYTM) at Outperform
September 14, 2026 6:11 AM - StreetInsider
KeyBanc Starts Rhythm Pharmaceuticals (RYTM) at Overweight
September 14, 2026 6:06 AM - StreetInsider
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
September 10, 2026 8:00 AM - StreetInsider
Deutsche Bank Starts Rhythm Pharmaceuticals (RYTM) at Hold
August 27, 2026 4:35 PM - StreetInsider
Rhythm gets Japan approval for obesity drug Imcivree
August 24, 2026 8:03 AM - StreetInsider
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
August 24, 2026 8:00 AM - StreetInsider
Form 4 RHYTHM PHARMACEUTICALS, For: Aug 17 Filed by: Joshi Manher
August 18, 2026 5:36 PM - SEC Filing
Form 3 RHYTHM PHARMACEUTICALS, For: Aug 17 Filed by: Joshi Manher
August 18, 2026 5:17 PM - SEC Filing
Form 4 RHYTHM PHARMACEUTICALS, For: Aug 13 Filed by: Shulman Joseph
August 17, 2026 6:00 PM - SEC Filing
Form 4 RHYTHM PHARMACEUTICALS, For: Aug 13 Filed by: Garfield Alastair
August 17, 2026 5:58 PM - SEC Filing
Rhythm Pharmaceuticals names Manher Joshi as chief medical officer
August 17, 2026 8:00 AM - StreetInsider
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
August 17, 2026 8:00 AM - StreetInsider
Form 4 RHYTHM PHARMACEUTICALS, For: Aug 13 Filed by: Lee Jennifer Kayden
August 14, 2026 7:05 PM - SEC Filing
Form 4 RHYTHM PHARMACEUTICALS, For: Aug 12 Filed by: Mazabraud Yann
August 14, 2026 7:02 PM - SEC Filing
Form 144 RHYTHM PHARMACEUTICALS, Filed by: Garfield Alastair
August 13, 2026 4:51 PM - SEC Filing
Form 144 RHYTHM PHARMACEUTICALS, Filed by: Shulman Joseph
August 13, 2026 4:41 PM - SEC Filing
Form 144 RHYTHM PHARMACEUTICALS, Filed by: Lee Jennifer Kayden
August 13, 2026 4:40 PM - SEC Filing
Form 144 RHYTHM PHARMACEUTICALS, Filed by: Mazabraud Yann
August 12, 2026 4:34 PM - SEC Filing
Form 144 RHYTHM PHARMACEUTICALS, Filed by: Cramer Pamela J.
August 11, 2026 4:31 PM - SEC Filing
UK regulator expands Imcivree approval to hypothalamic obesity
August 11, 2026 8:00 AM - StreetInsider
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired H
August 11, 2026 8:00 AM - StreetInsider
Form 144 RHYTHM PHARMACEUTICALS, Filed by: Cramer Pamela J.
August 10, 2026 4:34 PM - SEC Filing
Rhythm Pharmaceuticals (RYTM) PT Raised to $146 at JPMorgan
August 7, 2026 9:09 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Raised to $155 at RBC Capital
August 5, 2026 7:54 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Raised to $160 at Citizens on Imcivree Launch
August 5, 2026 4:19 AM - StreetInsider
Form 10-Q RHYTHM PHARMACEUTICALS, For: Jun 30
August 4, 2026 4:06 PM - SEC Filing
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
August 4, 2026 4:01 PM - StreetInsider
Form 8-K RHYTHM PHARMACEUTICALS, For: Aug 04
August 4, 2026 7:49 AM - SEC Filing
Rhythm Pharmaceuticals (RYTM) Tops Q2 EPS by 8c
August 4, 2026 7:17 AM - StreetInsider
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
August 4, 2026 7:01 AM - StreetInsider
Rhythm Pharmaceuticals RM-718 shows BMI reduction in Phase 2 trial
August 4, 2026 6:55 AM - StreetInsider
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
August 4, 2026 6:55 AM - StreetInsider
JPMorgan Starts Rhythm Pharmaceuticals (RYTM) at Overweight
July 27, 2026 3:04 AM - StreetInsider
Full Article List
